Romanian Journal of Laboratory Medicine

Revista Romana de Medicina de Laborator

Romanian Review of Laboratory Medicine

<abstract><title style='display:none'>Abstract</title> Heart failure (HF) is a common condition, especially in older patients. Considering the increase of life expectancy the total number of HF patients is expected to grow in the future, which makes HF an important focus of research. New high-throughput techniques, such as the “omics” (genomics, transcriptomics, metabolomics) have brought new insight into disease pathophysiology, facilitating the discovery of an impressive number of candidate biomarkers. In this review we consider different perspectives on the evaluation and clinical potential of biomarkers in heart failure as their usefulness in clinical settings is constantly being evaluated in order to bring them closer to the point-of-care. In addition, we examine recent advances in the methods of detection and quantification of biomarkers</abstract>

Abstract

“Iuliu Haţieganu” University of Medicine and Pharmacy, Department of Pharmacology, Physiology and Pathophysiology, Cluj-Napoca

“Iuliu Haţieganu” University of Medicine and Pharmacy, Department of Botanic and Molecular Biology, Cluj-Napoca

“Iuliu Haţieganu” University of Medicine and Pharmacy, Department of Toxicology, Cluj-Napoca

Keywords 

Cuvinte cheie 

<article-title>Advances in the detection and quantification of candidate and established biomarkers in heart failure</article-title>

Advances in the detection and quantification of candidate and established biomarkers in heart failure

<abstract><title style='display:none'>Abstract</title> Background: Pulmonary arterial hypertension (PAH) is an incapacitating disease even in childhood, associated with very poor prognosis. The disease is characterised by endothelial dysfunction. Two of the key endothelial mediators involved in the PAH pathogenesis are nitric oxide (NO) and angiotensinogen (AGT). Purpose of the study: to evaluate the following gene polymorphisms: endothelial nitric oxide synthase (eNOS) G894T, eNOS 4b/4a, and angiotensinogen (AGT) M235T, as well as allele frequency and their association with PAH in children. Material and methods This study included 32 children with pulmonary arterial hypertension secondary to congenital heart disease, 46 children with congenital heart disease without pulmonary arterial hypertension referred to the Pediatric Cardiology Clinic Tg.Mures and 40 healthy controls. All patients underwent a complete physical with NYHA class evaluation, echocardiographic exam and eNOS (G894T, 4b/4a) as well as AGT M235T polymorphisms determination. Results The frequency of eNOS 894T allele (p &lt; 0.0001) was significantly higher in patients with pulmonary arterial hypertension. Conclusions Our results advocate that there is a correlation between eNOS 894T allele and pulmonary arterial hypertension in children</abstract>

University of Medicine and Pharmacy Tg. Mureş – Pediatric Cardiology Clinic Tg.Mureş

Institute of Cardiovascular Diseases and Transplantation Tg. Mureş – Pediatric Cardiology Clinic

University of Medicine and Pharmacy Tg. Mureş - Pediatric Clinic Tg.Mureş

University of Medicine and Pharmacy Tg. Mureş - Genetics Department

<article-title>The role of eNOS and AGT gene polymorphisms in secondary pulmonary arterial hypertension in Romanian children with congenital heart disease </article-title>

The role of eNOS and AGT gene polymorphisms in secondary pulmonary arterial hypertension in Romanian children with congenital heart disease 

<abstract><title style='display:none'>Abstract</title> Listeria monocytogenes represents an important hazard to human health because it is capable of causing listeriosis, an atypical foodborne disease with a high fatality rate.The aim of this study was to detect and serotype Listeria monocytogenes in some food products (of animal and vegetable origin), collected during the 2011 period. The detection of Listeria monocytogenes was performed by ISO 11290- 1-A1/2004 standard method and verified by real-time PCR. Numerous subtyping strategies have been developed to characterize Listeria monocytogenes isolates. Serotyping, the traditional method for the subtype characterization of Listeria monocytogenes is not very discriminatory, but it is a universal method which gives important information on prevalence of specific serotypes. The confirmation of Listeria monocytogenes isolated strains was performed by a TaqMan real-time PCR assay, using TaqMan Pathogen Detection Kits (Applied Biosystems). The assay use specific primers and a probe for Listeria monocytogenes. In this study on a total number of 260 samples, 25 (9.61%) gave positive results for Listeria monocytogenes by conventional method and only 22 (8.46%) of them were confirmed by real-time PCR. These results indicate a high efficiency of the real-time PCR method in a short time, compared with classical methods which can provide false positive results. Four different Listeria monocytogenes serotypes were found in nine varieties of food products: 1/2a, 1/2b, 1/2c and 4b</abstract>

University of Agricultural Science and Veterinary Medicine, Iasi, Faculty of Veterinary Medicine, Public Health Department

<article-title>Detection and serotyping of Listeria monocytogenes in some food products from North-East of Romania</article-title>

Detection and serotyping of Listeria monocytogenes in some food products from North-East of Romania

<abstract><title style='display:none'>Abstract</title> Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal stem cell disorders characterized by ineffective hematopoiesis with dysplastic changes in one or more myeloid cell lines and increased risk of progression to acute leukemia. The current diagnosis criteria include the morphology of peripheral blood (PB) and bone marrow (BM), bone marrow biopsy and cytogenetic exam. Material and method. For this study, we have analyzed 33 patients diagnosed with lower-risk MDS (IPSS 0 and intermediate-1) according to the World Health Organization (WHO) classification (2001) between 2008 and 2012. The diagnosis was confirmed by blood cell counts, bone marrow (aspirate and biopsy) exam and cytogenetic exam. Other causes of cytopenia or dysplastic changes were excluded. Results. The types of MDS according to the WHO classification were: nine patients with refractory anemia (RA) (27.27%), sixteen patients with refractory anemia with ringed sideroblasts (RARS) (48.48%), and eight patients with refractory cytopenia with multilineage dysplasia (RCMD) (24.24%) out of which two with refractory cytopenia with multilineage dysplasia with ringed sideroblasts (RCMD-RS). Cytogenetic exam was performed in all patients, but analyzable metaphases for cytogenetic exam were obtained only from twenty five patients. The patients who did not have analyzable metaphases on cytogenetic exam were considered low risk if: they had only one cytopenia and the percent of bone marrow blasts was less than 5%. For all patients who had analyzable metaphases at cytogenetic exam, the International Prognostic Scoring System (IPSS) and Revised International Prognostic Scoring System (R-IPSS) scores were determined, and their survival and the death leading events were observed. According to IPPS (1997), the cytogenetic exam was good in 17 cases, intermediate in 1 case and poor in 7 cases. The IPSS score was low in 13 cases and intermediate-1 in 12 cases. According to R-IPSS, cytogenetic exams had been very good and good in 17 cases, intermediate in 1 case, poor in 6 cases and very poor in 1 case. R-IPSS was very low and low in 17 cases and intermediate and high in 8 cases. Conclusions. This new R-IPSS score at diagnosis allows a more accurate classification of patients into risk groups and thus enables risk adapted therapy</abstract>

Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania

University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania

Hematology Department, Coltea Hospital, Bucharest, Romania

National Centre for Prevention and Diseases Control, Bucharest, Romania

<article-title>The importance of the new prognostic scoring system for evaluating patients with lower-risk myelodysplastic syndrome at diagnosis</article-title>

The importance of the new prognostic scoring system for evaluating patients with lower-risk myelodysplastic syndrome at diagnosis

<abstract><title style='display:none'>Abstract</title> Background/aim: T lymphocytes are important players of the immune response. B-CLL is characterized by several immune defects. Our study aims to characterize the distinct maturational and functional T/NK cell subsets within B-cell chronic lymphocytic leukemia disease Rai stages. Patients and methods: Peripheral blood mononuclear cells from 43 patients enrolled in the study (16 females and 27 males, aged 68±10, 8 Rai 0, 22 Rai 1/2 and 13 Rai 3/4) were analyzed by multiparameter flow cytometry. Distinct subsets within the CD4+ (naive, central memory, effector/peripheral memory, regulatory-Tregs, follicular-TFH, CXCR3+ and/or CCR4+), CD8+ (naive+memory, effector, senescent) and NK (CD57+ and/or CD94+) were identified and compared between disease Rai stages. Results: Total numbers of T lymphocytes increase with disease stage. Both CD4+ and CD8+ T cells are elevated in absolute counts. The majority of CD4+ T cells are antigen-experienced, with increased Tregs, TFH and CXCR3+ (Th1-associated profile) T cell counts. The CD8+ T cells expansion is due mostly to the senescent CD57+ subset. No significant difference within NK subsets was observed among different disease stages. Conclusions: B-CLL behaviour seems to be associated with increased numbers of TFH and Tregs. The therapeutic modulation of T cell response in B-CLL patients may play an important role in the disease behaviour and may be a key event compensating for the immunodeficiency occurring mostly in advanced stages of the disease.</abstract>

University of Medicine and Pharmacy Grigore T. Popa of Iasi, Romania

Regional Institute of Oncology, Iasi, Laboratory of Molecular Biology

<article-title>Rai stage-related changes within T/NK cell populations from B-CLL patients</article-title>

Rai stage-related changes within T/NK cell populations from B-CLL patients

{"article-title":"Rai stage-related changes within T/NK cell populations from B-CLL patients"}

<abstract><title style='display:none'>Abstract</title> Pediatricians frequently encounter hematuria in children. One of the tardy complication of pulmonary tuberculosis, which is most characteristic and common in teenagers and middle aged, is represented by genitourinary tuberculosis. Renal tuberculosis is rare during childhood. The authors present a series of cases where the presenting symptom was gross or microscopic persistent hematuria. The diagnosis of urogenital tuberculosis was established from early-morning urine culture in all cases. In a patient with symptoms of recurrent urinary tract infection or hematuria associated with sterile pyuria the suspicion of GUTB must be considered. A delayed diagnosis of renal tuberculosis led to kidney damage and sequels of GUTB, including renal failure. Our cases report emphasizes that in case of persistent hematuria GUTB may be considered as a differential diagnosis</abstract>

Pediatric Department, University of Medicine and Pharmacy Tg. Mures, Romania, Tg. Mures, Romania

Pediatric Clinic No 2, Tg. Mures, Romania

Microbiology Department, University of Medicine and Pharmacy Tg. Mures, Romania, Tg. Mures, Romania

Genetic Department, University of Medicine and Pharmacy Tg. Mures, Romania, Tg. Mures, Romania

<article-title>Genitourinary tuberculosis in children - a diagnostic challenge</article-title>

Genitourinary tuberculosis in children - a diagnostic challenge

{"article-title":"Genitourinary tuberculosis in children - a diagnostic challenge"}

<abstract><title style='display:none'>Abstract</title> Background. The Down syndrome is a severe disease without pathogenic therapy. The only possibility to reduce the consequences of disease is prenatal screening and diagnosis. The gold standard in prenatal diagnosis is the conventional banding cytogenetic analysis of fetal cells obtained by invasive procedures. To reduce the complications, in the last years different methods to detect fetal cells or DNA in maternal blood were developed. Aim. The aim of study was to verify the reliability of quantification by immunoprecipitation of methylated fetal DNA in maternal blood in the prenatal diagnosis of 21 trisomy. Method. We analyzed probes from 12 pregnant women (7 with confirmed 21 trisomy pregnancy and 5 with normal pregnancy), with two being rejected for technical considerations. For each probe we carried out: extraction of total DNA (maternal and fetal), DNA fragmentation, immunoprecipitation of methylated DNA, washing, isolation of DNA and qPCR for immunoprecipitated DNA. To highlighting specific methylated regions on fetal 21 chromosome we used eight pairs of specific primers for chromosome 21. Finally we analysed the results of qPCR applying the formula D=- 6.331+0.959XEP4+1.188XEP5+0.424XEP6+0.621XEP7+0.028XEP8+0.387XEP10-0.683XEP11+ 0.897XEP12, where XEPi= fraction value for each marker. Results. In all normal pregnancies the value of D factor was negative concordant with absence of trisomy (100% specificity). In 5 from 6 pregnancies with 21 trisomy the value of D factor was positive, which indicated a high sensibility. However, to a precise estimation of this method is required a larger number of cases that allowing the obtaining of statistically validated results.</abstract>

University of Medicine and Pharmacy “Grigore T. Popa” Iaşi, Department of Medical Genetics

Regional Institute of Oncology Iaşi, Department of Molecular Biology

”Cuza Vodă” Obstetrical and Gynaecology Hospital Iaşi, Department of Prenatal Diagnosis

”Filantropia” Obstetrical and Gynaecology Hospital Bucharest, Department of Prenatal Diagnosis

University of Medicine and Pharmacy “Iuliu Haţieganu” Cluj Napoca, Department of Medical Genetics

University of Medicine and Pharmacy “Grigore T. Popa” Iaşi, Department of Obstetric and Gynaecology

<article-title>Prenatal diagnosis of 21 trisomy by quantification of methylated fetal DNA in maternal blood: study on 10 pregnancies</article-title>

Prenatal diagnosis of 21 trisomy by quantification of methylated fetal DNA in maternal blood: study on 10 pregnancies

<abstract><title style='display:none'>Abstract</title> Introduction: Multidrug-resistant tuberculosis (MDR-TB) represents an important public health problem. Rapid molecular methods detect the mutations responsible for drug- resistance and can shorten the time required for diagnosis and initiation of appropriate therapy. The objectives of our study were to optimize a multiplex allele-specific PCR technique (MAS-PCR) to detect rpoB mutations and to specify the type and frequency of these mutations. Material and methods: We have tested 47 non-duplicate MDR-TB, including extensively drugresistant tuberculosis (XDR-TB) strains, identified during 2007-2012, using MAS-PCR for detection of mutations in rpoB codons 531, 526 and 516. Results: The most common mutation was located in codon 531 (63.82%), while only 12.76% and 10.63% of the strains showed mutations in codon 516 and 526, respectively; for six strains we have not identified mutation in the targeted codons. Conclusion: MAS-PCR revealed the mutations prevalent in our region, with good sensitivity (87.2%), suggesting the usefulness of this test in the rapid diagnosis of MDR-TB</abstract>

“Grigore T. Popa” University of Medicine and Pharmacy Iaşi, Microbiology Department

“St. Parascheva” Clinical Hospital of Infectious Diseases Iaşi

“St. Spiridon” Clinical Emergency Hospital Iaşi

National Institute of Public Health – Regional Center of Public Health Iaşi

<article-title>Molecular detection of rifampicin resistance in multidrug-resistant Mycobacterium tuberculosis strains from North-Eastern Romania</article-title>

Molecular detection of rifampicin resistance in multidrug-resistant Mycobacterium tuberculosis strains from North-Eastern Romania

<abstract><title style='display:none'>Abstract</title> Eosinophils are leukocytes with multiple functions in physiologic and pathologic circumstances. Eosinophilia is typically associated with reactive conditions (helmintic infections, allergic or drug reactions and atopic disorders) and sometimes with hematologic and non- hematologic malignancies. Evaluation of a patient with eosinophilia requires numerous imaging investigations and laboratory tests for establishing the right treatment. We measured the degree of eosinophilic activation using serologic biomarkers such as serum eosinophil cationic protein (ECP) , interleukin-5 (IL-5) and eosinophilic cationic protein/eosinophil count (ECP/Eo) ratio in order to differentiate earlier among distinct eosinophilic conditions: clonal, non-clonal with malignancy and reactive eosinophilia with inflammation. The median ECP value in eosinophilic patients was significantly higher when compared to that of the control group (19.55 vs. 4.93 ng/mL, p&lt;0.05). Within patients with eosinophilia, the clonal eosinophilia group showed a significantly higher median ECP value compared to the median ECP values of the non-clonal eosinophilia groups - (30.15 vs. 19.5 ng/mL, p&lt;0.05 and respectively 30.15 vs. 13.3 ng/mL, p&lt;0.05). Also patients having non-clonal eosinophilia with malignancy had a significantly higher median ECP value compared to those of reactive eosinophilia and inflammation (19.5 vs. 13.3 ng/mL, p&lt;0.05). While ECP serum levels seemed to be a discriminatory tool for different groups of eosinophilic patients IL-5 and ECP/Eo were less useful for this purpose. However our results must be confirmed in larger studies</abstract>

Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

Coltea Clinical Hospital, Bucharest, Romania

Central Laboratory Synevo, Chiajna- Ilfov, Romania

Polytechnic University of Bucharest, Romania

<article-title>Eosinophil activation markers in clonal and non-clonal eosinophilia</article-title>

Eosinophil activation markers in clonal and non-clonal eosinophilia

{"article-title":"Eosinophil activation markers in clonal and non-clonal eosinophilia"}

<abstract><title style='display:none'>Abstract</title> Morphological and immuno- flow cytometry assisted analysis of peripheral blood and bone marrow are mandatory investigations in the diagnosis of acute leukemia. Cytology and immunophenotyping complement each other primarily because they have as common object malignant cell phenotype as a whole. The aim of our study was to analyze correlations between cytology and immunophenotyping on a group of patients investigated for acute myeloid leukemia. In our study the degree of correlation between blast percentage determined by cytology and immunophenotyping was low (r=0.049). The degree of correlation between myeloperoxidase positivity in cytochemistry and immunophenotyping was also low, with better results for cytochemistry. Expression of immunophenotypic markers was consistent with the composition of our group regarding French-American-British classes, except for HLA-DR (49.0%), TdT (3.77%), CD14 (5.66%), CD15 (5.66%). We also discuss the importance of interpreting with caution positivity for erythroid and megakaryocytic markers and differential diagnosis of cases simultaneously expressing CD7 and CD56. In conclusion, interpretation of immunophenotyping by flow citometry, done in close conjunction with morphology, is mandatory to facilitate the use of optimized sample processing methods and of standardized panels, for both appropriate diagnosis and follow-up.</abstract>

Oncology Institute Professor Doctor Ioan Chiricuta, Hematology Department, Cluj-Napoca

University of Medicine and Pharmacy Professor Doctor Iuliu Hatieganu, Cluj-Napoca

University of Medicine and Pharmacy, Targu-Mures

<article-title>Correlation of cytomorphology with flowcytometric immunophenotyping in acute myeloid leukemia</article-title>

Correlation of cytomorphology with flowcytometric immunophenotyping in acute myeloid leukemia

Dept. of Nephrology, County Clinical Emergency Hospital Timisoara

”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania

Dept. of Hematology, Clinical Hospital No.2 Timisoara

<article-title>Tubular injury in multiple myeloma</article-title>

{"article-title":"Tubular injury in multiple myeloma"}

Revista Romana de Medicina de Laborator is covered by the following services: <ul> <li> Baidu Scholar </li> <li> Cabell's Whitelist </li> <li> CABI (over 50 subsections) </li> <li> Case </li> <li> CNKI Scholar (China National Knowledge Infrastructure) </li> <li> CNPIEC - cnpLINKer </li> <li> Dimensions </li> <li> DOAJ (Directory of Open Access Journals) </li> <li> EBSCO </li> <li> EMCare </li> <li> ExLibris </li> <li> Google Scholar </li> <li> Index Copernicus </li> <li> Japan Science and Technology Agency (JST) </li> <li> J-Gate </li> <li> Journal Citation Reports/Science Edition </li> <li> JournalGuide </li> <li> JournalTOCs </li> <li> KESLI-NDSL (Korean National Discovery for Science Leaders) </li> <li> Meta </li> <li> MyScienceWork </li> <li> Naver Academic </li> <li> Naviga (Softweco) </li> <li> ProQuest </li> <li> Publons </li> <li> QOAM (Quality Open Access Market) </li> <li> ReadCube </li> <li> SCImago (SJR) </li> <li> Semantic Scholar </li> <li> Sherpa/RoMEO </li> <li> TDNet </li> <li> Ulrich's Periodicals Directory/ulrichsweb </li> <li> WanFang Data </li> <li> Web of Science - Science Citation Index Expanded </li> <li> WorldCat (OCLC) </li> <li> X-MOL </li> </ul>

Revista Romana de Medicina de Laborator ist in den folgenden Services indiziert: <ul> <li> Baidu Scholar </li> <li> Cabell's Whitelist </li> <li> CABI (over 50 subsections) </li> <li> Case </li> <li> CNKI Scholar (China National Knowledge Infrastructure) </li> <li> CNPIEC - cnpLINKer </li> <li> Dimensions </li> <li> DOAJ (Directory of Open Access Journals) </li> <li> EBSCO </li> <li> EMCare </li> <li> ExLibris </li> <li> Google Scholar </li> <li> Index Copernicus </li> <li> Japan Science and Technology Agency (JST) </li> <li> J-Gate </li> <li> Journal Citation Reports/Science Edition </li> <li> JournalGuide </li> <li> JournalTOCs </li> <li> KESLI-NDSL (Korean National Discovery for Science Leaders) </li> <li> Meta </li> <li> MyScienceWork </li> <li> Naver Academic </li> <li> Naviga (Softweco) </li> <li> ProQuest </li> <li> Publons </li> <li> QOAM (Quality Open Access Market) </li> <li> ReadCube </li> <li> SCImago (SJR) </li> <li> Semantic Scholar </li> <li> Sherpa/RoMEO </li> <li> TDNet </li> <li> Ulrich's Periodicals Directory/ulrichsweb </li> <li> WanFang Data </li> <li> Web of Science - Science Citation Index Expanded </li> <li> WorldCat (OCLC) </li> <li> X-MOL </li> </ul>

<DIV align=left> Please submit your manuscripts to Romanian Journal of Laboratory Medicine via Editorial System <A href="http://www.editorialsystem.com/rrml/">www.editorialsystem.com/rrml/</A> <A href="http://www.rrml.ro/instr_autori/license_to_publish.pdf">License to publish</A> Open Access Statement The journal is an Open Access journal that allows a free unlimited access to all its contents without any restrictions upon publication to all users. </DIV>

<DIV align=left> The Romanian Journal of Laboratory Medicine is official publication of the Romanian Association of Laboratory Medicine, published on a quarterly basis since December 2005. The close relationship between laboratory investigations and human general pathology requires the laboratory medicine as a necessary interdisciplinary specialty, needed for evidence-based medical practice. The objective of the journal is to publish high quality papers prepared especially by young scientists from all over the world, with emphasis on matters of Laboratory Medicine (Clinical Biochemistry, Immunology, Hematology, Microbiology, Genetics and Molecular Biology). The Romanian Journal of Laboratory Medicine seeks to be a forum where all practitioners and researchers interested in the field are able to disclose the results of their work or to share their views on the theoretical aspects of laboratory medicine. Publication frequency: four issues per year (January, April, July and October). Journal abbreviation: RJLabMed Why subscribe RJLabM is a peer-reviewed journal publishing original scientific and professional articles, editorials, general reviews, case reports, guidelines and recommendations of national and international scientific and professional bodies, abstract books for events (congresses, symposia, courses) in the field of Laboratory Medicine. Why submit RJLabM is an Open Access journal, which permit free access to its content for target audience. The Editorial Board and Scientific Reviewers are outstanding scientists ensuring high quality information within the journal. The peer-review system provided by experts is fair and constructive. Rejection Rate: 75 % Average time to first decision: 15 days Average time to final decision: 90 days Archiving Sciendo archives the contents of this journal in <A href="https://www.portico.org/">Portico</A> - digital long-term preservation service of scholarly books, journals and collections. Plagiarism Policy The editorial board is participating in a growing community of <A href="https://www.crossref.org/services/similarity-check/">Similarity Check System's</A> users in order to ensure that the content published is original and trustworthy. Similarity Check is a medium that allows for comprehensive manuscripts screening, aimed to eliminate plagiarism and provide a high standard and quality peer-review process. </DIV>

Editor-in-Chief Prof. Minodora Dobreanu, MD, PhD Department of Laboratory Medicine University of Medicine, Pharmacy, Sciences and Technology George Emil Palade Târgu Mureș, România Tel/fax: +40 265 217 425 E-mail: <A href="mailto:minodora.dobreanu@rrml.ro">minodora.dobreanu@rrml.ro</A> Deputy Editor Prof. Adrian Man, MD, PhD Department of Microbiology University of Medicine, Pharmacy, Sciences and Technology George Emil Palade Târgu Mureș, România E-mail: <A href="mailto:adrian.man@rrml.ro">adrian.man@rrml.ro</A> Editorial secretariat Assoc prof. Adina Huțanu, MD, PhD University of Medicine, Pharmacy, Sciences and Technology George Emil Palade Târgu Mureș, România E-mail: <A href="mailto:office@rrml.ro">office@rrml.ro</A> Advisory BoardProf. Dr. Maurizio Ferrari (Univ. "Vita-Salute San Raffaele", Milan, Italy) - Genetics and molecular biology Prof. Dr. Steliana Huhulescu (Institut für med. Mikrobiologie und Hygiene, Viena, Austria) - Microbiology Prof. Dr. Trefor Higgins (DynaLIFE Dx Laboratories, Edmonton, Canada) - Clinical biochemistry Prof. Dr. Janos Kappelmayer (Univ. Debrecen, Hungary) - Hematology Prof. Evi Lianidou (University of Athens, Greece) - Circulant nucleic biomarkers Prof. Dr. Laszlo Muszbek (Univ. Debrecen, Hungary) - Hemostasis Prof. Dr. Manuela Neuman (Institute of Drug Research, Univ. of Toronto, Canada) - Toxicology Prof. Dr. Francisco Nogales (Universidad de Granada, Spain) - Pathology Prof. Dr. Vladimir Palicka (Univ. Hradek Kralove, Praga, Czech Republic) - Laboratory Medicine Prof. Dr. Grazyna Odrowaz-Sypniewska (Nicolaus Copernicus University, Torun, Poland) - Laboratory Medicine Prof. Dr. Dan Simionescu (Clemson University, USA) - Medical research Prof. Dr. Ana Maria Simundic (Univ. Zagreb, Croatia) - Preanalytical Dr. Cristina Skrypnyk (Arabian Gulf University, Manama, Bahrain) - Genetics Prof. Dr. Robert Soslow (Memorial Sloan Kettering Cancer Center, New York, USA) - Pathology Prof. Dr. Horia Stănescu (University College London, UK) - Genetics Dr. Cătălina Suzana Stîngu (Universitätsklinikum Leipzig, Germany) - Microbiology Prof. Dr. Franc Strle (University Medical Centre Ljubljana, Slovenia) - Clinical Trials, Infectious Diseases Associate Prof. Dr. Alexandru Șchiopu Jr. (Lund University, Malmö, Sweden) - Medical research Prof. Dr. Petru Cianga (UMF "Gr. T. Popa" Iași, Romania) - Immunology Prof. Dr. Nicolae Hâncu (UMF "Iuliu Hatieganu", Cluj-Napoca, Romania) - Metabolic diseases Dr. Dan Oțelea (Institutul Național de Boli Infecțioase "Matei Balș", Romania) - Virology Prof. Dr. Adrian Streinu- Cercel (UMF "Carol Davila" București, Romania) - Infectious Diseases Assistant Editors Clinical Biochemistry and Immunology Prof. Dr. Minodora Dobreanu (University of Medicine Pharmacy, Sciences and Technology of Târgu Mureș, România) Dr. biol. Doina Ramona Manu (Center for Advanced Medical and Pharmaceutical Research of UMPhTîrgu Mureș, România) Associate Prof. Cristina Dimitriu (University of Medicine and Pharmacy „Gr.T.Popa” Iași) Associate Prof. Ioana Brudasca (University of Medicine and Pharmacy „Iuliu Hatieganu” Cluj-Napoca, România) Genetics and Molecular Medicine Prof. Dr. Claudia Bănescu (University of Medicine Pharmacy, Sciences and Technology of Târgu Mureș, România) Dr. George Valeriu Moldovan (University of Medicine Pharmacy, Sciences and Technology of Târgu Mureș, România) Hematology Dr. Cristina Elena Selicean (Oncology Institute „Prof. Dr. Ioan Chiricuta”, Cluj-Napoca, România) Dr. Cristina Mambet (University of Medicine Pharmacy Carol Davila, București) Microbiology Associate Prof. Dr. Edit Szekely (University of Medicine Pharmacy, Sciences and Technology of Târgu Mureș, România) Prof. Dr. Adrian Man (University of Medicine Pharmacy, Sciences and Technology of Târgu Mureș, România) Research &amp; Experimental Medicine Prof. Dr. Alina Scridon (University of Medicine Pharmacy, Sciences and Technology of Târgu Mureș, România) Prof. Dr. Camil Vari (University of Medicine Pharmacy, Sciences and Technology of Târgu Mureș, România) Histology, Pathology Lect. Dr. Adela Nechifor-Boilă (University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureș, România) Internal Medicine Associate Prof. Dr. Simona Cernea (University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureș, România) Statistics Prof. Dr. Marius Marusteri (University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureș, România) Lect. Dr. Marian Pop (University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureș, România) Lect. Dr. Mihaela Iancu (University of Medicine and Pharmacy „Iuliu Hatieganu” Cluj-Napoca, România) Language Editor Anisoara Pop (University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureș, România) Adrian Năznean (University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureș, România) Aurora Pașcan (University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureș, România) Emanuela Tegla (University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureș, România) Website/Research integrity editor Prof. Dr. Adrian Man (University of Medicine Pharmacy, Sciences and Technology of Târgu Mureș, România) Contact <A href="mailto:office@rrml.ro">office@rrml.ro</A> Publisher (on behalf of University of Medicine and Pharmacy Tîrgu Mureș, România) De Gruyter Poland Bogumiła Zuga 32A Str. 01-811 Warsaw, Poland T: +48 22 701 50 15

Ediciones

Revista y Edición

Revista Romana de Medicina de Laborator

Buscar

Volumen 21 (2013): Edición 3 (September 2013)

Detalles de publicación y publicación

Buscar

Artículos

Planifique su conferencia remota con Sciendo